David H. Sherr, PhD
Professor
Boston University School of Public Health
Dept of Environmental Health

PhD, Cornell University



Since 1993, David Sherr's laboratory has conducted research on how common environmental pollutants, such as dioxins, polycyclic aromatic hydrocarbons and PCBs, adversely affect the growth and behavior of several different types of normal and malignant cells. In previous work, the Sherr laboratory studied how environmental chemicals affect the development of the immune system. In specific, his laboratory demonstrated that aromatic hydrocarbons (generated by the combuston of any carbon source) compromise the function of bone marrow cells required for the development of antibody-forming cells. These cells are critical for immune protection against viruses and bacteria. This work had its orignis in Dr. Sherr's graduate studies on the ontogeny of lymphocyte development.

More recently, Dr. Sherr's laboratory has focused on the molecular mechanisms that initiate and maintain breast cancer and on the effects of environmental chemicals on these processes. The laboratory has shown that a cellular protein receptor, referred to as the aryl hydrocarbon receptor (AhR), plays an important role in the initiation and progression of human breast cancer. The results explain, in part, the association between environmental chemical exposure and breast cancer risk. Perhaps most importantly, these studies demonstrate that the AhR drives human breast cancer cells to invade and, presumably, metastasize even in the absence of environmental chemicals. These observations have led to the development of AhR inhibitors which block AhR activity and prevent tumor cells from invading. One immediate goal of the laboratory, therefore, is the development of potent AhR inhibitors as novel, targeted therapeutics to be used for treatment of all breast cancers but especially for treatment of "triple negative" or chemotherapy-resistant breast cancers. Interestingly, preliminary studies suggest that these AhR inhibitors could be useful for treatment of several other cancer cell types.

A new area of study in Dr. Sherr's laboratory is the analysis of the role of the AhR in blood cell development. These studies are important from both an environmental science and medical science point of view. Studies performed to date suggest that the AhR plays an important roll in the normal development of blood cells. The results suggest the intriguing possibility that common environmental pollutants can alter normal blood cell development by interfering with AhR signaling.

Dr. Sherr came to BUSPH from the faculty of Harvard Medical School, where he had earlier been a postdoctoral fellow in the department of Nobel Laureate Baruj Benacerraf. The Sherr Laboratory is funded by research grants from the National Institute of Environmental Health Sciences, the NIH Superfund Basic Research Program, and the Art BeCAUSE breast cancer foundation. Dr. Sherr is the Director of the Boston University Immunology Training Program, and a member of the Amyloid Treatment Research Program, the BU Cancer Center, the Hematology/Oncology Training Program, and the BU Hormone-dependent Cancer Center. He has trained 21 postdoctoral (M.D. or Ph.D.) and 11 predoctoral (M.D. and/or Ph.D.) fellows.

Graduate Faculty (Primary Mentor of Grad Students)
Boston University School of Medicine, Division of Graduate Medical Sciences


Professor
Boston University School of Medicine
Pathology & Laboratory Medicine


Director
Boston University
Superfund Research Program


Director
Boston University
Immunology Training Program



2014-2016 Avon Foundation: Research Award


The Role of the Aryl Hydrocarbon Receptor (AHR) in Autoimmunity and Tumor Immunity
01/25/2018 - 01/25/2021 (PI)
AnTolRx, Inc.

Defining the role of the AHR in Blood Cell Specification
01/01/2016 - 11/30/2020 (PI)
NIH/National Institute of Environmental Health Sciences
5R01ES025409-03

Superfund Research Program at Boston University
08/01/2017 - 03/31/2020 (PI)
NIH/National Institute of Environmental Health Sciences
5P42ES007381-22

Research Training in Immunology
09/01/2014 - 08/31/2019 (PI of Sub-Project / SP)
PI: Thomas Kepler, PhD
NIH/National Institute of Allergy & Infectious Diseases
5T32AI007309-28

Receptor-based Developmental and Reproductive Toxicity of Superfund Chemicals
04/01/2016 - 07/31/2017 (PI)
NIH/National Institute of Environmental Health Sciences
4P42ES007381-20

The Role of an Environmental Chemical Receptor in Development and Popagation of Cancer Stem Cells in Triple Negative and Inflammatory Breast Cancer
03/01/2016 - 04/20/2017 (PI)
Avon Breast Cancer Crusade, LLC.


Epidemiology of Immunotoxicant Exposure in Children
07/01/2011 - 02/28/2017 (PI)
President and Fellows of Harvard College NIH NIEHS
5R01ES012199-10

Receptor-based Developmental and Reproductive Toxicity of Superfund Chemicals
09/20/2012 - 03/31/2016 (PI)
NIH/National Institute of Environmental Health Sciences
5P42ES007381-19

The Role of an Environmental Chemical Receptor in Development and Propagation of Cancer Stem Cells in Triple Negative and Inflammatory Breast Cancer
07/01/2014 - 02/29/2016 (PI)
Avon Foundation


Stress Granules and the Biology of TDP-43
03/01/2012 - 12/31/2015 (SP Co-PI of Sub-Project / SP)
PI: Benjamin Wolozin, MD, PhD
NIH/National Institute of Environmental Health Sciences
5R01ES020395-04

Showing 10 of 29 results. Show All Results



Yr Title Project-Sub Proj Pubs
2018 Defining the Role of the AHR in Blood Cell Specifications 5R01ES025409-03 1
2018 Superfund Research Program at Boston University 5P42ES007381-22 314
2018 Core A: Administrative Core 5P42ES007381-22-8619 314
2018 Core-005: Training Core 5P42ES007381-22-6458 314
2017 Defining the Role of the AHR in Blood Cell Specifications 5R01ES025409-02 1
2017 Superfund Research Program at Boston University 2P42ES007381-21 314
2017 Core A: Administrative Core 2P42ES007381-21-8619 314
2017 Core-005 2P42ES007381-21-6458 314
2016 Defining the Role of the AHR in Blood Cell Specifications 1R01ES025409-01A1 1
2016 Receptor-based developmental and reproductive toxicity of Superfund chemicals 4P42ES007381-20 314
Showing 10 of 61 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Narasimhan S, Stanford Zulick E, Novikov O, Parks AJ, Schlezinger JJ, Wang Z, Laroche F, Feng H, Mulas F, Monti S, Sherr DH. Towards Resolving the Pro- and Anti-Tumor Effects of the Aryl Hydrocarbon Receptor. Int J Mol Sci. 2018 May 07; 19(5).View Related Profiles. PMID: 29735912.
     
  2. Krishnan S, Ding Y, Saedi N, Choi M, Sridharan GV, Sherr DH, Yarmush ML, Alaniz RC, Jayaraman A, Lee K. Gut Microbiota-Derived Tryptophan Metabolites Modulate Inflammatory Response in Hepatocytes and Macrophages. Cell Rep. 2018 Apr 24; 23(4):1099-1111. PMID: 29694888.
     
  3. Leung A, Zulick E, Skvir N, Vanuytsel K, Morrison TA, Naing ZH, Wang Z, Dai Y, Chui DHK, Steinberg MH, Sherr DH, Murphy GJ. Notch and Aryl Hydrocarbon Receptor Signaling Impact Definitive Hematopoiesis from Human Pluripotent Stem Cells. Stem Cells. 2018 Mar 23.View Related Profiles. PMID: 29569827.
     
  4. Rothhammer V, Borucki DM, Kenison JE, Hewson P, Wang Z, Bakshi R, Sherr DH, Quintana FJ. Detection of aryl hydrocarbon receptor agonists in human samples. Sci Rep. 2018 Mar 21; 8(1):4970.View Related Profiles. PMID: 29563571.
     
  5. Wang, Z, Novikov O, Stanford-Zulick EA, Kenison-White J., Sherr DH. National Academy of Sciences, The Promise of Genome Editing to Advance Environmental Health Research Workshop. Tracking an AHR Regulatory Circuit in Cancer with AHR Inhibitors and CRISPR/Cas9 Knockdown. Washington DC. 2018.
     
  6. Shashar M, Belghasem ME, Matsuura S, Walker J, Richards S, Alousi F, Rijal K, Kolachalama VB, Balcells M, Odagi M, Nagasawa K, Henderson JM, Gautam A, Rushmore R, Francis J, Kirchhofer D, Kolandaivelu K, Sherr DH, Edelman ER, Ravid K, Chitalia VC. Targeting STUB1-tissue factor axis normalizes hyperthrombotic uremic phenotype without increasing bleeding risk. Sci Transl Med. 2017 Nov 22; 9(417).View Related Profiles. PMID: 29167396; DOI: 10.1126/scitranslmed.aam8475;.
     
  7. Ash PEA, Stanford EA, Al Abdulatif A, Ramirez-Cardenas A, Ballance HI, Boudeau S, Jeh A, Murithi JM, Tripodis Y, Murphy GJ, Sherr DH, Wolozin B. Dioxins and related environmental contaminants increase TDP-43 levels. Mol Neurodegener. 2017 05 05; 12(1):35.View Related Profiles. PMID: 28476168; DOI: 10.1186/s13024-017-0177-9;.
     
  8. Mulas F, Li A, Sherr DH, Monti S. Network-based analysis of transcriptional profiles from chemical perturbations experiments. BMC Bioinformatics. 2017 Mar 23; 18(Suppl 5):130.View Related Profiles. PMID: 28361664; DOI: 10.1186/s12859-017-1536-9;.
     
  9. Wang Z, Monti S, Sherr DH. The diverse and important contributions of the AHR to cancer and cancer immunity. 2017; 2:102-107.
     
  10. Commodore N, Ramirez-Cardenas A, Sherr DH. Emerging Researchers National Conference (ERN). Identifying antagonists of the aryl hydrocarbon receptor with biological activity in vitro. Washington DC. 2017.
     
Showing 10 of 218 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 210 publications over 36 distinct years, with a maximum of 15 publications in 1996

YearPublications
19802
19816
19821
19831
19843
19853
19864
19872
19882
19903
19925
19941
19952
199615
19976
19984
19995
20008
20014
20025
20037
20049
200513
200610
20078
20088
20096
20106
20114
20124
20139
201411
20154
201614
201710
20185
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Aryl hydrocarbon receptor
Breast cancer and the environment
Immunology
Toxicology
Contact for Mentoring:


72 E. Concord St Housman (R)
Boston MA 02118
Google Map


Sherr's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department